TVRD
Tvardi Therapeutics, Inc.
NASDAQ: TVRD · HEALTHCARE · BIOTECHNOLOGY
$3.15
+2.94% today
Updated 2026-04-30
Market cap
$30.02M
P/E ratio
—
P/S ratio
559.61x
EPS (TTM)
$-3.26
Dividend yield
—
52W range
$3 – $44
Volume
0.0M
Tvardi Therapeutics, Inc. (TVRD) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $-5.49M | $-60.09M | $-17.87M | $-21.04M | $-60.92M | $-23.50M |
| Capital expenditures | $349000.00 | $39000.00 | $50000.00 | $2.38M | $1.05M | $0.00 |
| Depreciation | $1.01M | $1.55M | $85000.00 | $95000.00 | $192000.00 | — |
| Stock-based comp | — | — | $246000.00 | $314000.00 | $319000.00 | $1.40M |
| Free cash flow | $-5.84M | $-60.13M | $-17.92M | $-23.41M | $-61.96M | $-23.50M |
| Investing cash flow | $-20.27M | $-4.75M | $-22.00M | $22.47M | $48.74M | — |
| Financing cash flow | $39.14M | $46.61M | $4000.00 | $2000.00 | $-3.60M | — |
| Dividends paid | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — |